Collaboration, License and Option Agreements - Summary of Contract Assets and Liabilities (Details) $ in Thousands |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
USD ($)
| |
| Deferred revenue | |
| Deferred revenue as of beginning of period | $ 60,658 |
| Collaboration and license revenue recognized | (12,648) |
| Deferred revenue as of end of period | 48,010 |
| Collaboration and Stock Purchase Agreement | AbbVie | |
| Deferred revenue | |
| Deferred revenue as of beginning of period | 34,007 |
| Collaboration and license revenue recognized | (7,995) |
| Deferred revenue as of end of period | 26,012 |
| License and Stock Purchase Agreement | Gilead | |
| Deferred revenue | |
| Deferred revenue as of beginning of period | 26,651 |
| Collaboration and license revenue recognized | (4,653) |
| Deferred revenue as of end of period | $ 21,998 |